<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03557658</url>
  </required_header>
  <id_info>
    <org_study_id>THR-1442-C-455</org_study_id>
    <nct_id>NCT03557658</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Bexagliflozin in Subjects With Moderate Hepatic Impairment</brief_title>
  <official_title>A Phase 1, Open-label, Parallel-group Study to Evaluate the Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Bexagliflozin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theracos</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theracos</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the drug exposure and drug effects on subjects with
      moderate hepatic impairment after a single oral dose of bexagliflozin tablets, 20mg. The
      study will also evaluate how safe the study drug is and how well the study drug is tolerated
      in subjects with moderate hepatic impairment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 26, 2018</start_date>
  <completion_date type="Actual">December 26, 2018</completion_date>
  <primary_completion_date type="Actual">December 26, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax (Maximum observed plasma concentration)</measure>
    <time_frame>Up to 48 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax (Time of maximum observed plasma concentration)</measure>
    <time_frame>Up to 48 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2 (Apparent terminal elimination half-life)</measure>
    <time_frame>Up to 48 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf (Area under the plasma concentration-time curve from Time 0 to infinity)</measure>
    <time_frame>Up to 48 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary Glucose Excretion 0-48 hours</measure>
    <time_frame>0-48 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety as measured by number of adverse events</measure>
    <time_frame>Up to 16 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Type2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Hepatic Impaired</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Volunteer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bexagliflozin</intervention_name>
    <description>Bexagliflozin tablets, 20 mg</description>
    <arm_group_label>Healthy Volunteer</arm_group_label>
    <arm_group_label>Hepatic Impaired</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body-mass index (BMI) between 18.0 kg/m2 and 32.0 kg/m2.

          -  Willing and able to stay at the clinical research facility as required by the protocol

        Exclusion Criteria:

          -  History of allergy to drugs or latex.

          -  Donated a significant amount of blood in the past 2 weeks.

          -  Female subjects who are pregnant or breastfeeding.

          -  Not willing to use an adequate form of birth control during the study and for 30 days
             after discharge from clinic.

          -  Having taken the investigational drug in the past 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J. P. Lock, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Theracos Sub, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Site 1</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site 2</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>June 4, 2018</study_first_submitted>
  <study_first_submitted_qc>June 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 15, 2018</study_first_posted>
  <last_update_submitted>September 27, 2019</last_update_submitted>
  <last_update_submitted_qc>September 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

